Publication | Closed Access

Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115

National Cancer InstituteSolid TumorsMedicineCancer ManagementPharmacologyClinical TrialsPharmacotherapyCancer TreatmentOncologyCancer ResearchDaily×5 One-hour Infusion